It’s been a little over a year since U.S. regulators approved Genentech’s Ocrevus (ocrelizumab) as the first treatment for both relapsing and progressive forms of multiple sclerosis (MS) — a disabling neurological disease now believed to affect nearly one million Americans. While the jury’s still out regarding the therapy’s long-term effectiveness and safety, five MS patients we spoke to … Continue reading 5 MS Patients Across US Talk About How Ocrevus Has Changed Their Lives